{"id":968573,"date":"2026-05-29T08:04:33","date_gmt":"2026-05-29T12:04:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/"},"modified":"2026-05-29T08:04:33","modified_gmt":"2026-05-29T12:04:33","slug":"sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/","title":{"rendered":"SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting"},"content":{"rendered":"

\nData will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D
\n<\/h2>\n
\n

MIAMI, May 29, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq:\u00a0SABS<\/a>), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it will present data at two congresses in June. SAB BIO will present an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association\u00ae (ADA) being held June 5-8, 2026, in New Orleans, LA. The Company will also present a poster presentation at the Federation of Clinical Immunology Societies (FOCIS) 2026 Annual Meeting being held June 9-12, 2026, in San Francisco, CA. Data to be presented will highlight SAB BIO\u2019s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for newly diagnosed Stage 3 T1D patients.<\/p>\n

\u201cWe are pleased to participate in both ADA\u2019s 2026 Scientific Sessions and FOCIS 2026 to continue engaging with the broader diabetes and immunology communities. These forums provide an important opportunity to highlight SAB-142\u2019s clinical and mechanistic profile and to build further understanding of the potential for this unique multi-specific modality as we advance the program through the ongoing registrational Phase 2b SAFEGUARD study,\u201d said Alexandra Kropotova, M.D., MBA, Chief Medical Officer, SAB BIO<\/strong>. \u201cWe look forward to continuing to collaborate with the scientific community and to advance toward our topline data readout for SAFEGUARD in the 2H 2027.\u201d\u00a0\u00a0<\/p>\n

\n Oral Presentation at ADA\u2019s 2026 Scientific Sessions:<\/strong>\n <\/p>\n

\n Title<\/strong>:\u00a0Clinical Safety, Pharmacokinetics, Immunogenicity, and Pharmacodynamics following Repeat Dosing of SAB-142, a Fully Human Multi-Specific Antithymocyte Globulin for New-Onset Type 1 Diabetes<\/em>
Session:<\/strong>\u00a0Oral Presentations – Preventing Type 1 Diabetes
Presenter:<\/strong>\u00a0Christoph Bausch, PhD, MBA, Chief Operating Officer, SAB BIO
Presentation Date and Time:<\/strong>\u00a0Friday, June 05, 2026, 2:45 – 3:00 PM CT
Location:<\/strong> New Orleans Convention Center \u2013 Session Room 245 (Level 2)<\/p>\n

\n Poster Presentation at FOCIS 2026 Annual Meeting:<\/strong><\/p>\n

Title<\/strong>:\u00a0Positive Clinical Translation of a Juvenile NHP Study for Evaluating SAB-142, a Multi-Specific T-Cell Targeting T1D Therapy, in Humans<\/em>
Session:<\/strong> Exhibit and Poster Reception \u2013 Poster # W114
Presenter:<\/strong>\u00a0Diane Maher, PhD, Director, Program Management, SAB BIO
Presentation Date and Time:<\/strong> Wednesday, June 10, 2026, 6:50 – 8:05 PM PT
Location:<\/strong>\u00a0 San Francisco Marriott Marquis \u2013 Discovery Center Poster & Exhibit Hall \u2013 Salon 9<\/p>\n

The presentations will be made available in the Presentations<\/a> section of the Company\u2019s website afterwards\u00a0and will remain accessible following the conference.<\/p>\n

\n About SAB-142<\/strong>
\n
SAB-142 is a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D). SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action analogous to that of rabbit ATG (rATG). rATG has demonstrated in multiple clinical trials the ability to slow disease progression in patients with new- or recent-onset of Stage 3 T1D. SAB-142, like rATG, directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of \u201cbad acting\u201d T-lymphocytes. By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells.<\/p>\n

\n About SAB BIO<\/strong>
\n
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO\u2019s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company\u2019s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit\u00a0www.sab.bio<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
Certain statements made in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cto be,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cseem,\u201d \u201cseek,\u201d \u201cfuture,\u201d \u201coutlook,\u201d and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the development and clinical trial results of the Company\u2019s T1D program and other discovery programs.<\/p>\n

These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry\u2019s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned \u201cRisk Factors\u201d in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at\u00a0https:\/\/www.sec.gov\/<\/a>. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.<\/p>\n

\n CONTACTS<\/strong>\n <\/p>\n

\n Investor Relations:<\/strong>
\n
Christine Ryan
ir@sab.bio<\/a><\/p>\n

\n Media:<\/strong>
\n
Sheila Carlson
media@sab.bio<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D MIAMI, May 29, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq:\u00a0SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it will present data at two congresses in June. SAB BIO will present an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association\u00ae (ADA) being held June 5-8, 2026, in New Orleans, LA. The Company will also present a poster presentation at the Federation of Clinical Immunology Societies (FOCIS) 2026 Annual Meeting being held June 9-12, 2026, in San Francisco, … <\/p>\n

Continue reading “SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-968573","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D MIAMI, May 29, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq:\u00a0SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it will present data at two congresses in June. SAB BIO will present an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association\u00ae (ADA) being held June 5-8, 2026, in New Orleans, LA. The Company will also present a poster presentation at the Federation of Clinical Immunology Societies (FOCIS) 2026 Annual Meeting being held June 9-12, 2026, in San Francisco, … Continue reading "SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T12:04:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODM1OSM3NjIxNjM2IzIyMjE3NDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting\",\"datePublished\":\"2026-05-29T12:04:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/\"},\"wordCount\":1035,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODM1OSM3NjIxNjM2IzIyMjE3NDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/\",\"name\":\"SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODM1OSM3NjIxNjM2IzIyMjE3NDE=\",\"datePublished\":\"2026-05-29T12:04:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODM1OSM3NjIxNjM2IzIyMjE3NDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODM1OSM3NjIxNjM2IzIyMjE3NDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - Market Newsdesk","og_description":"Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D MIAMI, May 29, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq:\u00a0SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it will present data at two congresses in June. SAB BIO will present an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association\u00ae (ADA) being held June 5-8, 2026, in New Orleans, LA. The Company will also present a poster presentation at the Federation of Clinical Immunology Societies (FOCIS) 2026 Annual Meeting being held June 9-12, 2026, in San Francisco, … Continue reading \"SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-29T12:04:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODM1OSM3NjIxNjM2IzIyMjE3NDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting","datePublished":"2026-05-29T12:04:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/"},"wordCount":1035,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODM1OSM3NjIxNjM2IzIyMjE3NDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/","name":"SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODM1OSM3NjIxNjM2IzIyMjE3NDE=","datePublished":"2026-05-29T12:04:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODM1OSM3NjIxNjM2IzIyMjE3NDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODM1OSM3NjIxNjM2IzIyMjE3NDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-associations-2026-scientific-sessions-and-focis-2026-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SAB BIO to Present Data on SAB-142 at The American Diabetes Association\u2019s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=968573"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968573\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=968573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=968573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=968573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}